Humacyte Secures $60 Million in Oversubscribed Stock Offering to Advance Bioengineered Tissue Platform
Humacyte's successful $60 million capital raise provides critical funding to accelerate development of its universally implantable bioengineered human tissues, which have received multiple FDA designations and could transform treatment for vascular trauma, dialysis access, and other medical conditions.
Humacyte Inc. has secured approximately $60 million through an oversubscribed registered direct offering, positioning the biotechnology company to advance its portfolio of universally implantable bioengineered human tissues. The commercial-stage company entered into a securities purchase agreement with fundamental institutional investors for the offering, which will provide crucial capital to support ongoing clinical development and commercialization efforts.
The company will issue 28,436,018 shares of common stock and accompanying warrants at $2.11 per unit, with the warrants becoming exercisable 180 days after issuance and carrying an exercise price of $2.11 per share. These financial instruments expire on April 7, 2031, providing long-term investment potential for participating institutions. Gross proceeds from the offering are expected to reach $60 million before deducting fees and expenses, with closing anticipated around October 8, 2025. D. Boral Capital LLC served as the exclusive placement agent for the transaction.
This capital infusion comes at a pivotal moment for Humacyte, following the Food and Drug Administration's approval of the company's Biologics License Application for its acellular tissue engineered vessel in extremity vascular trauma in December 2024. The company's technology platform represents a significant advancement in regenerative medicine, developing bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve patient outcomes across multiple medical conditions.
Humacyte's pipeline includes late-stage clinical trials targeting vascular applications beyond trauma, including arteriovenous access for hemodialysis and peripheral artery disease. The company's 6mm acellular tissue engineered vessel for AV access in hemodialysis previously received both the FDA's Regenerative Medicine Advanced Therapy designation and Fast Track designation, highlighting the therapeutic potential of this innovation. Additional RMAT designations have been granted for the treatment of urgent arterial repair following extremity vascular trauma and for advanced peripheral artery disease.
The company's preclinical development program extends to coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. The strategic importance of Humacyte's technology has been recognized at the federal level, with the acellular tissue engineered vessel receiving priority designation for vascular trauma treatment from the U.S. Secretary of Defense. For additional information about the company's technology platform and development programs, visit https://humacyte.com/.
The successful completion of this oversubscribed offering demonstrates strong institutional confidence in Humacyte's technology platform and its potential to address significant unmet medical needs across multiple therapeutic areas. The funding will support the company's efforts to bring innovative tissue engineering solutions to patients while advancing its broader pipeline of bioengineered human tissues and organ systems.